Migraine Drugs Market - By Type (Abortive Medicine and Preventive Medicine), By Route of Administration (Oral, Injection, and Others), and By Distribution Channel (Hospital-Based Pharmacies, Retail Pharmacies and Online Pharmacies) and – By Region - Global Opportunity Analysis and Industry Forecast, 2020 – 2030

DFS020344  | 
: Life Sciences & Healthcare  | 
Mar-2024  | 
Upcoming  | 
Pages: NA  | 
Tables: NA  | 
Figures: NA
We’ve been tracking the direct impact of COVID-19 on this market, as well as the indirect impact from other industries. The report will incorporate these insights.

Migraine Drugs Market is expected to reach USD 10.1 million by 2030 from USD 2.5 million in 2020, growing at a CAGR of 15.2%. Migraine is a common neurological disease categorized by continuing attacks of severe hurting head pain. Frequently unilateral, the headaches can last from four hours to three days. These headaches generally occur on one side of the head and each episode of migraine has different duration and intensity. Migraine drugs are employed in the treatment of headaches related with migraine. Pain is often allied with other symptoms such as nausea, vomiting, increased sensitivity to light (photophobia), increased sensitivity to sound (photophobia), tingling or numbness in the edges or legs, sweating, and diarrhea. Migraines are more frequent in women, with 17.0% women reporting an attack compared to 6.0% men, every year. This is recognized to the changes in estrogen levels in females, especially during menstruation. Besides, hormonal medications, such as oral contraceptives and hormone replacement therapy may further worsen migraine in women. Therefore, increase in the global female population is projected to propel the growth of migraine drugs market.  

Market Segmentation:

On the basis of treatment type, the global migraine drugs market is segmented into Abortive Medicine and Preventive Medicine. On the basis of route of administration, the global market is classified as oral, injectable, and others. On the basis of the distribution channel, the market is diversified as hospital pharmacies, retail pharmacies, and others. Geographic breakdown and analysis of each of the aforesaid segments includes regions comprising North America, Europe, Asia-Pacific, and RoW.  

Market Dynamics and Factors:

The increasing awareness regarding a precautions of the migraine coupled with the availability of various options for the treatment are the major factors responsible for boosting the growth of the market. A number of administrations including the American Headache and Migraine Association are taking efforts to spread awareness about a migraine and hence coming up with programs and providing support to patients so as to spread awareness about the disease and further disorders related to a headache. In accumulation, increasing incidence of chronic disease, rising consumption of unhealthy food are the factors anticipated to propel growth of the global migraine drugs market. However, side effects associated with migraine drugs is a factor that hinders the market growth. On the conflicting, the presence of growth opportunities in emerging nations is expected to provide new opportunities for the key players.

Geographic Analysis:

Rise in focus of vendors on the emergent markets, such as Asia-pacific and LAMEA, is expected to increase the market growth. The Asia pacific is projected to dominate the global migraine drugs market and is further expected to continue this trend in the near future. This high growth is mainly due to the demand for better healthcare facilities and improvements in healthcare infrastructure, increasing number of people having from a migraine and rising public awareness of the disease in this region. Furthermore, this region presents remarkable opportunities for the venture capitalists and investors, as the developed markets are moderately saturated. In addition, India and china are the major rising countries contributing to the global migraine drugs market growth in the Asia pacific region, this is mainly due to the high frequency of a migraine in these countries. Rising focus on niche products and their launches along with high penetration of novel drug manufacturers will further have a positive impact on the growth of the global migraine drugs market in the upcoming years.

Competitive Scenario:

The major key players in the migraine drugs market are Abbott Laboratories, Allergan Plc., AstraZeneca, Endo International Plc., Vernalis, Glaxo Smith Kline Plc., Royalty Pharma, Impax Laboratories, Johnson & Johnson, Merck & Co., and Pfizer Inc.

Migraine Drugs Market Report Scope

Report Attribute

Details

Market size value in 2020

USD 10.1 million

Growth Rate

CAGR of 15.2% from 2021 to 2030

Forecast period

2021 - 2030

Quantitative units

Revenue in USD billion 2020 to 2030 and CAGR from 2021 to 2030

Report coverage

Revenue forecast, Market Share Analysis, Sales Analysis, Competitor Analysis, Growth factors, and trends, Macro-economic indicator analysis, PORTER's Five Forces analysis, Pricing Analysis, PESTEL Analysis, Value Chain Analysis, COVID-19 Impact Analysis

Segments covered

y Type (Abortive Medicine and Preventive Medicine), By Route of Administration (Oral, Injection, and Others), and By Distribution Channel (Hospital-Based Pharmacies, Retail Pharmacies and Online Pharmacies)

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Key Country scope

U.S.; Canada; Mexico; U.K.; Germany; France; Italy; Spain; Japan; China; India; Malaysia; Singapore; South Korea; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Turkey

Key companies profiled

o    Abbott Laboratories
o    Allergan Plc.
o     AstraZeneca
o    Endo International Plc.
o    Vernalis
o    Glaxo Smith Kline Plc.
o    Royalty Pharma
o    Impax Laboratories
o    Johnson & Johnson
o    Merck & Co.
o    Pfizer Inc.

TOC REQUEST


KEY MARKET SEGMENTS:

  • Global Migraine Drugs Market – By Type
    • Synthetic Leather
      • (PU and PVC)
    • Genuine leather
    • Polymers
    • Fabrics
  • Global Migraine Drugs Market – By Route of Administration
    • Introduction
    • Oral
    • Injection
    • Others
  • Global Migraine Drugs Market – By Vehicle Type
    • Passenger Vehicles
    • Light Commercial Vehicles
    • Heavy Commercial Vehicles
  • Global Migraine Drugs Market – By Geography
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • U.K.
      • France
      • Germany
      • Italy
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • India
      • Australia
      • Rest of Asia Pacific
    • ROW
      • Latin America
      • Middle East
      • Africa

KEY PLAYERS
o    Abbott Laboratories
o    Allergan Plc.
o     AstraZeneca
o    Endo International Plc.
o    Vernalis
o    Glaxo Smith Kline Plc.
o    Royalty Pharma
o    Impax Laboratories
o    Johnson & Johnson
o    Merck & Co.
o    Pfizer Inc.


 


 
©2024 Decision Foresight. All Rights Reserved.